OTOF-GT (SENS-501)
Otoferlin Deficiency
Phase 1/2Active; 6-month follow-up data expected T1 2026
Key Facts
Indication
Otoferlin Deficiency
Phase
Phase 1/2
Status
Active; 6-month follow-up data expected T1 2026
Company
About Sensorion
Sensorion's mission is to find solutions for hearing disorders by building a portfolio of innovative therapies through its three strategic pillars: Restore, Treat, and Prevent. The company leverages a unique internal R&D platform to advance its pipeline, with key assets like OTOF-GT in Phase 1/2 and SENS-401 in Phase 2. Its clear strategy focuses on addressing a large, underserved market in inner ear diseases through both proprietary development and strategic partnerships.
View full company profile